Ultromics, a health-tech company which applies AI to echocardiography, to earlier detect and better diagnose heart disease, has entered a know-how and clinical research agreement with Mayo Clinic. Underpinned by a determination to drive higher standards of patient care, the collaboration will leverage Mayo’s cardiology expertise and insights and feed real world data into Ultromics’ first product to market, EchoGo Core.
Mayo Clinic is one of the world’s leading centers of cardiology and its extensive cardiac datasets will assist Ultromics in the development of the company’s image analysis product suite. The collaboration will be led by Ross Upton, CEO and founder of Ultromics and Patricia A. Pellikka, M.D. cardiologist and clinical researcher at Mayo Clinic, who this week joined Ultromics’ scientific advisory board. Mayo Clinic will also take an equity stake in the company.
EchoGo Core, cleared by the FDA for use by US physicians in November 2019, applies AI and automates the analysis of echocardiograms, measuring key cardiac parameters to support decision-making with zero variability.
Heart disease is the number one cause of death globally, killing 18m people a year, of whom 17m are under 70 years of age and include young people who die of undiagnosed heart disease (Sudden Cardiac Death) and pregnant women.
Announcing the agreement Ross Upton, said: “Our absolute focus is on increasing the diagnostic accuracy of cardiovascular disease which will ultimately help transform lives through the development of new diagnostic and predictive solutions.”
To learn more about how EchoGo could benefit medical practices and patients, visit https://ultromics.com/echogo
EchoGo Core is FDA Cleared for use in the United States, not CE Marked for use in the European Union.